Nils L. Visser

The Netherlands Cancer Institute

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

The Netherlands Cancer Institute

Research Subjects

Research Interests

Nils L. Visser has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

Carine Dufau
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
12 shared publications
Daniel S. Peeper
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
12 shared publications
Daniela Mercedes D’EMpaire Altimari
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
12 shared publications
Elisabeth H. Jin
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
12 shared publications
Hester H. Van Boven
The Netherlands Cancer Institute 13 Department of Pathology Amsterdam, the Netherlands
12 shared publications
Juan Simon Nieto
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
12 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
TCGA and DepMap data, related to Figure 5 and S4
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
TCGA and DepMap data, related to Figure 5 and S4
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Genome-wide drug-anchored CRISPR-Cas9 screens identify targetable pathways to sensitize to DDLPS therapies, related to Figure 1
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Genome-wide drug-anchored CRISPR-Cas9 screens identify targetable pathways to sensitize to DDLPS therapies, related to Figure 1
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Supplementary Table S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Supplementary Table S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
RNA seq data, related to Figure 3, S3, S4, and 5
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S5 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
RNA seq data, related to Figure 3, S3, S4, and 5
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
(non-)essential gene lists, readcounts CRISPR screens, MAGeCK output, related to Figure 1 and S1
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
(non-)essential gene lists, readcounts CRISPR screens, MAGeCK output, related to Figure 1 and S1
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Perturbation of NHEJ-related genes sensitizes specifically to low-dose doxorubicin, related to Figure 2
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Perturbation of NHEJ-related genes sensitizes specifically to low-dose doxorubicin, related to Figure 2
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
All sgRNA sequences used in this study
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
All sgRNA sequences used in this study
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Perturbation of TDP2 or DNA-PKcs strongly increases cell cycle arrest and senescence induction by low-dose doxorubicin, related to Figure 3
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Perturbation of TDP2 or DNA-PKcs strongly increases cell cycle arrest and senescence induction by low-dose doxorubicin, related to Figure 3
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
TDP2-/- plus low-dose doxorubicin activates p53 in MDM2 amplified DDLPS, related to Figure 5
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
TDP2-/- plus low-dose doxorubicin activates p53 in MDM2 amplified DDLPS, related to Figure 5
Open Access
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Gene sets used in this study, related to Figure 3 and S3
Website
Google Scholar
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S6 from Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence
by Thijs Jalving, Carine Dufau, Juan Simon Nieto, Daniela M. D’EMpaire Altimari, Susan E. van Hal-Van Veen, Elisabeth H. Jin, Nils L. Visser, Hester H. Van Boven, Winette T.A. van der Graaf, Winan J. van Houdt, et al.
Gene sets used in this study, related to Figure 3 and S3

Show all